Zimmer Biomet Holdings, Inc. (NYSE:ZBH) SVP Sells $150,649.20 in Stock

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) SVP Lori Winkler sold 1,443 shares of the firm’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Zimmer Biomet Trading Up 2.4 %

NYSE ZBH opened at $107.87 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm has a market cap of $21.47 billion, a PE ratio of 24.24, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The company has a 50 day moving average price of $105.55 and a 200 day moving average price of $107.19. Zimmer Biomet Holdings, Inc. has a 52 week low of $97.69 and a 52 week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the firm posted $2.20 earnings per share. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.89%. Zimmer Biomet’s payout ratio is 21.57%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ZBH. JMP Securities restated a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Truist Financial reiterated a “hold” rating and issued a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Raymond James reduced their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Royal Bank of Canada reduced their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $124.15.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Siemens Fonds Invest GmbH increased its stake in Zimmer Biomet by 561.8% during the 4th quarter. Siemens Fonds Invest GmbH now owns 15,002 shares of the medical equipment provider’s stock valued at $1,585,000 after purchasing an additional 12,735 shares in the last quarter. Menard Financial Group LLC purchased a new stake in shares of Zimmer Biomet in the 4th quarter valued at $30,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Zimmer Biomet in the 4th quarter valued at $14,432,000. Jefferies Financial Group Inc. boosted its holdings in shares of Zimmer Biomet by 28.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 18,680 shares of the medical equipment provider’s stock valued at $1,973,000 after acquiring an additional 4,133 shares during the last quarter. Finally, Integrated Advisors Network LLC boosted its holdings in shares of Zimmer Biomet by 12.3% in the 4th quarter. Integrated Advisors Network LLC now owns 4,022 shares of the medical equipment provider’s stock valued at $425,000 after acquiring an additional 441 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.